Buchumschlag

Drug-induced mast cell eradication: a novel approach to treat mast cell activation disorders?

Mast cell (MC) activation is a key event in allergic reactions, other inflammatory states, and MC activation syndromes. MC-stabilizing agents, mediator-targeting drugs, and drugs interfering with mediator effects are often prescribed for these patients. However, the clinical efficacy of these drugs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Valent, Peter (VerfasserIn) , Akin, Cem (VerfasserIn) , Hartmann, Karin (VerfasserIn) , Reiter, Andreas (VerfasserIn) , Gotlib, Jason (VerfasserIn) , Sotlar, Karl (VerfasserIn) , Sperr, Wolfgang R. (VerfasserIn) , Degenfeld-Schonburg, Lina (VerfasserIn) , Smiljkovic, Dubravka (VerfasserIn) , Triggiani, Massimo (VerfasserIn) , Horny, Hans-Peter (VerfasserIn) , Arock, Michel (VerfasserIn) , Galli, Stephen J. (VerfasserIn) , Metcalfe, Dean D. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: June 2022
In: The journal of allergy and clinical immunology
Year: 2022, Jahrgang: 149, Heft: 6, Pages: 1866-1874
ISSN:1097-6825
DOI:10.1016/j.jaci.2022.04.003
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jaci.2022.04.003
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0091674922004511
Volltext
Verfasserangaben:Peter Valent, Cem Akin, Karin Hartmann, Andreas Reiter, Jason Gotlib, Karl Sotlar, Wolfgang R. Sperr, Lina Degenfeld-Schonburg, Dubravka Smiljkovic, Massimo Triggiani, Hans-Peter Horny, Michel Arock, Stephen J. Galli, and Dean D. Metcalfe
Beschreibung
Zusammenfassung:Mast cell (MC) activation is a key event in allergic reactions, other inflammatory states, and MC activation syndromes. MC-stabilizing agents, mediator-targeting drugs, and drugs interfering with mediator effects are often prescribed for these patients. However, the clinical efficacy of these drugs varies depending on the numbers of involved MCs and the underlying pathology. One straightforward approach would be to eradicate the primary target cell. To date however, no MC-eradicating treatment approach has been developed for patients with MC activation disorders. Nevertheless, recent data suggest that long-term treatment with agents effectively inhibiting KIT function results in the virtual eradication of tissue MCs and a sustained decrease in serum tryptase levels. In many of these patients, MC depletion is associated with a substantial improvement in mediator-induced symptoms. In patients with an underlying KIT D816V-positive mastocytosis, such MC eradication requires an effective inhibitor of KIT D816V, such as avapritinib. However, the use of KIT inhibitors must be balanced against their potential side effects. Here we discuss MC-eradicating strategies in various disease models, the feasibility of this approach, available clinical data, and future prospects for the use of KIT-targeting drugs in MC activation disorders.
Beschreibung:Online verfügbar: 12. April 2022, Artikelversion: 3. Juni 2022
Gesehen am 12.02.2024
Beschreibung:Online Resource
ISSN:1097-6825
DOI:10.1016/j.jaci.2022.04.003

Ähnliche Einträge